ARX's Principal Activity is the the development, manufacture and distribution of products to improve the healing in complex wounds and soft tissue reconstruction.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-16.31%|
|vs ASX 200 (1yr)||-34.63%|
|ASX Rank||537 of 2,319|
|Sector Rank||40 of 199|
Aroa Biosurgery Limited (ARX) is a soft tissue regeneration company focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. It participates in the wound care and surgical reconstruction markets. Its products currently for sale in the key US market target chronic wounds and soft tissue reconstruction including, hernia, breast reconstruction and trauma/limb salvage/ tumour surgery.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|Ms Tracy Weimar||Joint Company Secretary||Jul 2020|
|Mr John Flower Diddams||Non-Executive Director||Nov 2019||
Mr John Flower Diddams
Mr Diddams has over forty years' experience as a CFO, CEO and director of both private and publicly listed companies. John has knowledge and experience in the practical application of ASX Listing Rules, Australian corporations' law, international accounting standards and corporate governance principles. He heads a CPA firm providing corporate advisory services to SME and mid-cap companies and has managed the listing process, secondary capital raisings and ASX listings in a number of industry sectors, including oil and gas, food and retail, telecommunications, adventure tourism, biotechnology, and the dental and medical sectors. John is currently a non-executive director of New Zealand based Volpara Health Technologies Limited (ASX:VHT) and Surf Lakes Holdings Limited. He is also Chair of the Risk Committee of the company.
|Mr Steven (Steve) Barnard Engle||Non-Executive Director||Apr 2015||
Mr Steven (Steve) Barnard Engle
Mr Engle has over 20 years of executive leadership experience with public biotech companies developing products in metabolic, autoimmune, oncologic and infectious disease areas. He is the Chief Executive Officer of CohBar, a clinical stage biotechnology company developing mitochondria-based therapeutics to treat age-related diseases and extend healthy lifespan. Before joining CohBar, Steven served as CEO of Averigon Consulting, an advisory firm to the life science industry, supporting companies through product partnering, regulatory planning, investor relations and executive management. Previously, he was Chairman and CEO of XOMA Corporation, a leader in the development of therapeutic antibodies and antibody technologies. Prior to XOMA, Steven served as Chairman and CEO of La Jolla Pharmaceutical Company. Earlier, he served as Vice President of Marketing for Cygnus, a drug delivery systems company, where he helped to gain FDA approval and to launch Nicotrol for smoking cessation. Steven is the non-executive Chairman of the Board of Prescient Therapeutics Ltd., an ASX listed clinical stage oncology company, and a director of the board of Author-it Software Corporation, a developer of authoring information solutions for pharmaceutical and biotechnology companies. He is a former director of industry associations, BIO, BayBio and BIOCOM, and was a Member of the board of the Lupus Foundation of America.
|Mr John Richard Pinion II||Non-Executive Director||Feb 2015||
Mr John Richard Pinion II
Mr Pinion has over 26 years of experience in biologic, small molecule pharmaceutical, gene therapy and device operations across Asia, Europe and the Americas. He joined Ultragenyx in July 2015 and currently holds the role of EVP, Translational Sciences and Chief Quality Operations Officer. He provides leadership for Ultragenyx's translational sciences functions which includes Pharmacology and Toxicology, Research and Bioanalytical Development, as well as GxP Quality and Compliance and CMC Analytical Development and QC. In the ten years prior to joining Ultragenyx, John has held roles of increasing responsibility at Genentech (subsequently Roche post Genentech acquisition), departing the organization as Senior Vice President and Global Head of Quality and Compliance for Pharma Technical Operations based in Basel, Switzerland. Previous to Genentech, John spent 17 years in operational and senior leadership roles in Baxter International's Renal, Bioscience, Parenterals and Device divisions. He is also member of the Risk Committee of the company.
|Mr James (Jim) Neil McLean||Non-Executive Chairman,Non-Executive Director||Aug 2011||
Mr James (Jim) Neil McLean
Non-Executive Chairman,Non-Executive Director
Mr McLean has gained 25 years experience serving as either Chair, Director, or an executive of research and technology businesses for both commercial and New Zealand Government organisations. In addition to Aroa, current appointments include Chair of Prevar Limited, R J Hill Laboratories Limited and Information Tools Limited. He was Chair of the New Zealand Institute of Plant & Food Research and Chair of its predecessor HortResearch, as well as several private businesses and start-up companies. He served on the board of the then Foundation for Research, Science, and Technology including five years as deputy Chair. Jim was an executive and director of Genesis Research & Development Corporation Limited during its early stages through public listing. Before focusing in science and technology businesses, Jim held management positions with an international manufacturing business and spent thirteen years as a partner at chartered accountants, EY. His time at EY was focused on business strategy and included two years' secondment to EY's Washington DC office. He is a member of the Risk Committee.
|Mr Philip John McCaw||Non-Executive Director||Mar 2008||
Mr Philip John McCaw
Mr McCaw is the Founding Partner of Movac, one of New Zealand's Venture Capital funds. Phil has over 20-years experience investing into New Zealand technology companies and helping to guide their growth. Phil was an early investor in Trade Me, New Zealand's on-line trading community, which was sold to Fairfax in 2006. He was also an early investor into PowerByProxi, a wireless power technology spin-out from Auckland University, which was sold to Apple in 2018. Outside of Movac, Phil remains an angel investor and maintains a personal angel investment portfolio. He is a advocate for the development of the entrepreneurial and early-stage investment eco-system in New Zealand and was the past Chair of the Angel Association of New Zealand; a founding investor in the Lightning Lab technology accelerator; and a founding investor in the Kiwi Landing Pad in San Francisco. Prior to starting Movac Phil spent 10-years with Deloitte Consulting working in New Zealand and the USA.
|Mr Brian Roderick Ward||Chief Executive Officer,Managing Director||Sep 2007||
Mr Brian Roderick Ward
Chief Executive Officer,Managing Director
Mr Ward has held senior corporate roles in life sciences and health care companies over the last 25 years. He has management experience in life science companies spanning clinical, technical, sales, marketing, corporate development and strategy having worked for a number of multinationals including Baxter, Beecham and SmithKline Beecham throughout the world. He has managed investments into New Zealand technology companies for the Foundation for Research Science and Technology, served as the founding CEO of NZBio, and has sat on a number of government and industry expert panels.
|Mr James Blair Agnew||Chief Financial Officer,Joint Company Secretary||N/A|
ARX directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|19/08/21||James (Jim) McLean||Buy||+102,400||$0.75||$76,800||Exercise of options|
|19/08/21||James (Jim) McLean||Exercise||102,400||$0.75||$76,800||Exercise of options|
|06/08/21||Philip McCaw||Transfer||2,864,879||$1.151||$3,298,621||Off-market transfer|
|11/06/21||Philip McCaw||Buy||+81,925||$0.75||$61,443||Exercise of options|
|11/06/21||Philip McCaw||Exercise||81,925||$0.75||$61,443||Exercise of options|
|22/02/21||John Diddams||Sell||+200,000||$1.193||($238,680)||On-market trade|
|09/12/20||John Diddams||Buy||+165,000||$0.107||$17,737||Exercise of options|
|09/12/20||John Diddams||Exercise||165,000||$0.107||$17,737||Exercise of options|
The current holdings of ARX directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|James (Jim) McLean||19/08/2021||2,674,708||N/A||204,800||N/A|
|John Pinion II||31/03/2021||N/A||N/A||879,000||N/A|
|Steven (Steve) Engle||31/03/2021||N/A||N/A||879,000||N/A|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|J P Morgan Nominees Australia Pty Limited||09/08/2021||24,401,862||7.15|
|National Nominees Limited||09/08/2021||22,112,806||6.48|
|Citicorp Nominees Pty Limited||09/08/2021||27,365,874||8.02|
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|09-08-21||Citicorp Nominees Pty Limited||27,365,874||--||8.02|
|09-08-21||J P Morgan Nominees Australia Pty Limited||24,401,862||--||7.15|
|09-08-21||National Nominees Limited||22,112,806||--||6.48|
12 month transaction history compiled from ASX announcements.
|Date||Name||Sold||Previous %||New %|
|Year||Closing Price||Last Trade|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.